The Claim
In non-diabetic adults with overweight or obesity, once-weekly semaglutide at a dose of 2.4 mg is associated with transient, mild-to-moderate gastrointestinal adverse events, most commonly nausea (44.2%), diarrhea (31.5%), and vomiting (24.8%), with 4.5% discontinuing treatment due to gastrointestinal events compared to 0.8% in the placebo group.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
People without diabetes who are overweight or obese and take a weekly 2.4 mg dose of semaglutide often get mild stomach issues like nausea, diarrhea, or vomiting, but most keep taking it — only a small number stop because of these side effects.
See the scientific wording
Once-weekly semaglutide at 2.4 mg is associated with transient, mild-to-moderate gastrointestinal adverse events in non-diabetic adults with overweight or obesity, with nausea (44.2%), diarrhea (31.5%), and vomiting (24.8%) being most common, leading to treatment discontinuation in 4.5% due to GI events, compared to 0.8% with placebo.
What the research says
1 studyStudy: Once-Weekly Semaglutide in Adults with Overweight or Obesity.
The study looked at the same medicine and dose as the claim and found similar stomach-related side effects that were usually mild and went away over time, with slightly more people stopping the drug because of these issues compared to placebo.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.